レンバチニブ,ペムブロリズマブ,TACEの併用は,中期期のHCC患者でPFSを有意に改善したが,重度の副作用の発生率は高かった. Combination of lenvatinib, pembrolizumab and TACE significantly improved PFS in intermediate-stage HCC patients, but with higher severe side effects rate.
リンバチニブとペンブロリズマブをトランス動脈性化学栓塞 (TACE) と併用した3期試験 (LEAP- 012),中期肝細胞癌 (HCC) の患者では,進行性生存率 (PFS) が有意に改善された. A phase 3 study, LEAP-012, found that the combination of lenvatinib and pembrolizumab with transarterial chemoembolization (TACE) significantly improved progression-free survival (PFS) for patients with intermediate-stage hepatocellular carcinoma (HCC). 平均PFSは14. 6ヶ月,TACE単独投与では10ヶ月でした. Median PFS was 14.6 months versus 10 months for TACE alone. 併用薬は有効でしたが,重度の副作用の発生率は71. 3%にも達しました. While the combination showed efficacy, it also resulted in higher rates of severe side effects, affecting 71.3% of patients.